All News
Filter News
Found 290 articles
-
IN8bio Appoints Alan S. Roemer as ChairmanFounding Leadership Team Member of Pharmasset, Roivant and Axovant Who Brings Extensive Life Sciences Experience
10/7/2020
IN8bio, Inc., a clinical-stage biotechnology company focused on developing innovative allogeneic, autologous and genetically modified gamma-delta T cell therapies for the treatment of cancers, announced that Alan S. Roemer, MBA, MPH has been appointed Chairman of the Company’s Board of Directors.
-
A disappointed Merck said it was reviewing its options for a possible appeal, while a pleased Gilead said if an appeal came, it was confident a higher court would come to the same verdict as the federal appeals court.
-
Healthcare Payments Innovator MAPay Tackles Inefficiencies in Global Healthcare Transactions
4/2/2019
MAPay, LLC, a global healthcare technology firm, has deployed a transformational healthcare payment network with an expanding customer base, positive patenting positions, increasing revenues, and multiple industry stakeholder acceptance.
-
Durham, NC-based Precision BioSciences set its initial public offering (IPO) price at $16 per share, raising $126.4 million. It began trading today on the Nasdaq under the ticker symbol DTIL.
-
BioSpace Movers and Shakers: March 15
3/15/2019
Biotech and pharma companies make changes to their executive leadership teams, with moves at Sandoz, PAREXEL, FSD, Karuna, Precision Bio, and more. -
Raymond Schinazi Joins Precision BioSciences Board of Directors
3/14/2019
Globally recognized leader in antiviral drug discovery and development
-
Antios Therapeutics Raises $25 Million in Oversubscribed Series A Financing to Pursue Hepatitis B Cure
11/27/2018
Antios Therapeutics, Inc. ("Antios") today announced the completion of a US$25 million oversubscribed Series A financing led by Lumira Ventures and Domain Associates, two prominent life science venture capital firms.
-
Petrichor Names Preeminent Scientist and Biotechnology Industry Entrepreneur Dr. Raymond F. Schinazi to Advisory Board
7/24/2018
Petrichor Healthcare Capital Management today announced the appointment of Raymond F. Schinazi, PhD, DSc (Hon) to its Advisory Board.
-
Federal court judge orders Merck to repay $2.5 Billion to Gilead in overturned patent decision.
-
Agenus Creates New Cell Therapy Subsidiary Named AgenTus Therapeutics
10/23/2017
Agenus today announced the launch of a subsidiary company for its cell therapy business, AgenTus Therapeutics.
-
Bruno Lucidi Appointed CEO of AgenTus Therapeutics, The Cell Therapy Subsidiary of Agenus
10/23/2017
Agenus Chairman and CEO Garo Armen Ph.D. announces the appointment of Bruno Lucidi as CEO of AgenTus Therapeutics.
-
Can Gilead Squeeze $12 Billion From Kite Pharma?
8/30/2017
-
Ambrosus Partners With Trek TherapeuticsTo Develop A Blockchain-Powered Method To Track Quality In Pharmaceutical Manufacturing
8/16/2017
-
The Bay Area Biotech That Generates Billions in Cash Flow Every Year (So Far)
5/10/2017
-
Millendo Therapeutics Appoints Mary Lynne Hedley, Ph.D. And Carole Nuechterlein, J.D. To Board Of Directors
4/11/2017
-
How Gilead Just Lost $9 Billion in Market Value This Week
2/10/2017
-
Struggling to Keep Its Head Above Water: Ophthotech to Review Strategic Alternatives and Shake Up C-Suite
2/1/2017
-
What You Need to Know About Blade Therapeutics
1/17/2017
-
Cornerstone Pharmaceuticals, Inc. Release: Pharma Announces Additions To Its Board Of Directors: Jean-Pierre Sommadossi, Ph.D., Richard Axel, M.D., Chi Van Dang, M.D., Ph.D., And Richard Scheller, Ph.D.
1/11/2017
-
Gilead Sinks, Will Pay Rival $2.54 Billion for a Patent Dispute
12/19/2016